296307
Chronic Kidney Disease and Metabolic Syndrome in Korean middle-aged Adults from 1998 through 2009
Methods The first, second, third and fourth Korea National Health and Nutrition Examination Survey (KNHANES I, II, III, and IV) was conducted by the Korea Institute for Health and Social Affairs for the Korean Ministry of Health and Welfare in 1998, 2001, 2005 and 2007-2009. The sample included 11,289 Korean men and women aged 45-64 years. Subjects were classified into two groups based on their baseline glomerular filtration rate (GFR) using the Chronic Kidney Disease Epidemiology Collaboration equation: 1) greater than or equal to 60 mL/min/1.73 m2 (non-CKD group; normal and mild renal dysfunction), and 2) less than 60 mL/min/1.73 m2 (CKD group; moderate, severe renal dysfunction, and renal failure). The MS was determined using National Cholesterol Education Program Adult Treatment Panel III criteria and the Asia-Pacific criteria for obesity based on waist circumference.
Results The distribution of CKD was 1.8%, 6.8%, 3.6% and 2.9% in 1998, 2001, 2005, and 2007-2009, respectively. The distribution of MetS was 41.4%, 41.9%, 39.7% and 34.3%, respectively. The adjusted odds ratio for MS was 6.26 (95% Confidence Interval (CI) 1.78-21.9), 2.96 (95% CI 1.02-8.54), 2.55 (95% CI 0.50-13.0), and 1.89 (95% CI 1.19-3.02) after adjustment for confounding factors, respectively.
Conclusions This community-based random sample drawn from the entire Korean middle aged population showed that MS was significantly associated with CKD.
Learning Areas:
Biostatistics, economicsChronic disease management and prevention
Epidemiology
Public health or related research
Learning Objectives:
Evaluate chronic kidney disease distrubution from 1998 to 2009 in KOREA population.
Keyword(s): Chronic Disease Management and Care, Chronic Disease Prevention
Qualified on the content I am responsible for because: I have designed and wrote this study as a first author.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.